Prospective studies carried out in Europe in large cohorts of children have changed the outlook of disease progression in the perinatal human immunodeficency virus type 1 infection (HIV-l) in the last years (1) . Life expectancy is higher than 13 years and most time is spent in a moderately symptomatic condition (2) . This picture refers to cohorts of children untreated or partially treated with the first transcriptase inhibitors, even zidovudine monotherapy.
A larger use of combination antiretroviral treatments and prophylactic drugs against opportunistic infections will be likely to slow or even halt the disease progression and improve survival. Thus, the goal is now not only a survival, rather a better quality of life (1) .
Many infected children in Italy are now approaching adolescence, attend secondary school, practise a sport (1). However, many factors make these children feel different from "normal" adolescents: pill taking, periodic clinical and laboratory checks, parents who are intravenous drug users, HIV -1 infected, sick, imprisoned, or deceased. Most childen present an HIV -1 related growth failure and pubertal delay (3), which are immediately obvious when HIV-1 infected children are at school or practise a sport as "normal" children of their own age do. This inevitably augments their feeling ofbeing different and their consequent psychological disconfort. We suggest that in the perspective of a global improvement of the quality of life of children with a chronic HIV -1 infection such these problems should be taken into consideration.
The cause of growth failure in infected children is postnatal in origin (as most children are infected at, or very close to, delivery and their birth weight is generally normal) and is due to many factors: psychosocial deprivation, chronic or recurrent infection, gastrointestinal abnormalities and neurologic disorders.
Metabolic and endocrine impairment may directly depend on HIV-1 infection or be secondary to the use of any of the medications required to treat HIV-1 infection and its complications. Among hormones which can affect growth, thyroid function has been extensively investigated: mild thyroid dysfunction is observed in some patients and the euthyroid sick syndrome, a hypothyroid-like regulation of the pituitary-thyroid axis (low FT3 and T3 serum levels, increased rT3 production), may be evident, particularly in patients with severe disease (4). However, it seems unlikely that these abnormalities may substantially affect growth in these patients.
Spontaneous and stimulated growth hormone (GH) release has been evaluated in some studies and conflicting results have been obtained; in fact, GH secretion may be normal in some children, while in other studies abnormalities of both stimulated and spontaneous GH secretion have been clearly demonstrated (4, 5) . HIV-I infection in children can lead to abnormal GH production and release after provocative stimulation. Several possible etiologies could explain the reduced GH secretion including cytomegalovirus or toxoplasmosis infection of the hypothalamicpituitary area (6, 7) and the release of cytokines (i.e. interleukin-I and tissue necrosis factor) (8). Moreover; in many children infection Insulin-Like Growth Factor 1 (IGF-I) is significantly reduced (4) and IGF-I resistance may contribute to poor growth (9) .
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As HIV -1 infection may selectively affect the hypothalamus and the pituitary gland, FSH and LH secretion may be consistently impaired in these patients and pubertal delay is the obvious consequence. The significant delay in bone age (relative to chonologic age) and the longer time needed by the HIV-l-infected hemophiliac boys older than 14 years of age to approach puberty suggest that pubertal delay (and possibly hypogonadotrophic hypogonadism) could be present at a greater extent in children with perinatallyacquired HIV-1 infection. Some studies have clearly demonstrated that HIV -l-positive males who had abnormalities of growth (either by height or growth velocity criteria) have lower age-adjusted testosterone levels compared with triggered HIV-I-negative subjects (10) . To the best of our knowledge no data are actually available on the estrogen serum levels in girls with HIV-1 infection. We suggest that the item should be a matter of urgent investigation.
Adrenal insufficiency is a commonly reported endocrine abnormality in HIV -l-infected patients (11) ; furthermore, some drugs (Le. ketoconazole, commonly used in treatment of Candida infection) may directly inhibit adrenal steroid synthesis and other drugs (i.e. megestrol, more rarely used in children) may cause secondary adrenal insufficiency because of their cortisol-like suppression of adrenalpituitary axis. Furthermore, in children with HIV-1 related disease, morning serum cortisol levels are reduced, particularly in patients with the lowest CD4+ cell counts; adrenal insufficiency seems to be not related to ACTH deficiency.
We emphasize that growth impairment should be early detected thus allowing timely treatment with recombinant human GH (rhGH) in early childhood. Recent experiences with recombinant human growth hormone in adults have given encouraging results: treatment with rhGH is able to increase body weight, lean body mass, and treadmill work output in patients iwith HIV-I associated wasting. Limited preliminary observations indicate the possibility of GH resistance in severe HIV-1 infected patients as high dose rhGH has limited effects in adults and the combination ofrhIGF-I and low dose rhGH has no significant anabolic effect in HIV-I' wasting (12) . Anyway, beneficial effect of rhqH in patients with symptomatic HIV-1 infection has been clearly documented (13) . Actually no studies are available on the effects ofrhGH in children with perinatallyacquired HIV-1 infection: the anabolic effects of GH might help children to get better growth and bone maturation. Megestrol acetate treatment in HIV -l-Infected children with growth failure is associated to weight gain, without any effect on linear growth; therefore this drug cannot help to improve growth and maturation in these patients (14) . Early detection of hypogonadism is also of relevant importance; FSH and LH secretion may be significantly impaired in these 'patients and spontaneous puberty cannot occur Early intervention with GH (i.e. at the age of 4-5 years) could prevent the impairment of linear Inducepuberty growth, improve the bone age/height age ratio and possibly ameliorate the outcome of growth and pubertal development. Nevertheless, administration of testosterone/estrogens to induce puberty (at bone age of 12 years) may have beneficial effects on these adolescents.
In conclusion, we suggest that research should complete our knowledge on the endocrinological outline of infected children; they should be monitored and timing GH and testosterone/estrogen replacement treatment should be introduced (table  1) . Optimization of hormonal therapy could improve growth, puberty, final height and, possibly, quality of life of long-term surviving children with perinatally-acquired HIV -1 infection.
